Grifols (Grifols) Debt-to-Equity : 1.74 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Grifols Debt-to-Equity?

Grifols's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $979 Mil. Grifols's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10,054 Mil. Grifols's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6,355 Mil. Grifols's debt to equity for the quarter that ended in Dec. 2023 was 1.74.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Grifols's Debt-to-Equity or its related term are showing as below:

GIKLY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 1.53 Max: 1.74
Current: 1.74

During the past 13 years, the highest Debt-to-Equity Ratio of Grifols was 1.74. The lowest was 0.00. And the median was 1.53.

GIKLY's Debt-to-Equity is ranked worse than
94.63% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs GIKLY: 1.74

Grifols Debt-to-Equity Historical Data

The historical data trend for Grifols's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Debt-to-Equity Chart

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.47

1.35

1.69

1.59

1.74

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	1.59	1.87	1.81	1.74

Competitive Comparison of Grifols's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Grifols's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Grifols's Debt-to-Equity falls into.

Grifols Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Grifols's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(979.188	+	10054.007)	/	6354.598
	=	1.74

Grifols's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(979.188	+	10054.007)	/	6354.598
	=	1.74

Grifols (OTCPK:GIKLY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Grifols Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Grifols's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.